Cargando…
Down-regulation of UBC9 increases the sensitivity of hepatocellular carcinoma to doxorubicin
UBC9 is an E2-conjugating enzyme that is required for SUMOylation and has been implicated in regulating several critical cellular pathways. UBC9 is overexpressed in certain tumors, such as lung adenocarcinoma, ovarian carcinoma and melanoma, which implies that it has special clinical significance. H...
Autores principales: | Fang, Sufen, Qiu, Junyao, Wu, Zheng, Bai, Tao, Guo, Wuhua |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5564807/ https://www.ncbi.nlm.nih.gov/pubmed/28572537 http://dx.doi.org/10.18632/oncotarget.17939 |
Ejemplares similares
-
Downregulation of UBC9 promotes apoptosis of activated human LX-2 hepatic stellate cells by suppressing the canonical NF-κB signaling pathway
por: Fang, Sufen, et al.
Publicado: (2017) -
Is Transthyretin a Regulator of Ubc9 SUMOylation?
por: Wieczorek, Elżbieta, et al.
Publicado: (2016) -
UBC9 coordinates inflammation affecting development of bladder cancer
por: Huang, Xiaoliang, et al.
Publicado: (2020) -
Ubc9 expression predicts chemoresistance in breast cancer
por: Chen, Shi-Feng, et al.
Publicado: (2011) -
Observation of an E2 (Ubc9)-homodimer by crystallography
por: Alontaga, Aileen Y., et al.
Publicado: (2016)